AZ's Zook adds MedImmune to his responsibilities

Share this article:
AstraZeneca's chief marketer Tony Zook is stepping in as interim head of MedImmune following the announcement that Dave Mott, president and chief executive of the biologics unit, will step down at the end of July. 

Zook will continue to serve as CEO of AstraZeneca's North American business and EVP of global marketing while dividing his time between AstraZeneca's Wilmington, DE, HQ and MedImmune in Gaithersburg, MD. 

“He'll be leaning on his leadership team here to continue driving the business,” said an AstraZeneca spokesperson.

The company would not disclose its timeframe for the search but said a process was in place for finding a permanent chief for MedImmune, which AstraZeneca acquired a year ago. MedImmune has since absorbed another AstraZeneca acquisition, Cambridge Antibody Technology, and the firm's other biologics operations, and has submitted a biologics license application for investigational monoclonal antibody motavizumab. 
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.